Study Effect of Vitamin D on the Immunopathology Responses of the Bronchi in Murine Model of Asthma

Linlin Feng; Tingting Meng; Yunyun Qi; Seyyed Shamsadin Athari; Xiaoyun Chen

doi:10.18502/ijaai.v20i5.7399

Linlin Feng Department of Pediatric, Taian City Central Hospital, Taian, China
Tingting Meng Department of Pediatric, Taian City Central Hospital, Taian, China
Yunyun Qi Department of Pediatric, Taian City Central Hospital, Taian, China
Seyyed Shamsadin Athari Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
Xiaoyun Chen Department of Pediatric, Taian City Central Hospital, Taian, China

DOI: https://doi.org/10.18502/ijaai.v20i5.7399

Keywords: Asthma; Allergy and immunology; Vitamin D

Abstract

Allergic asthma is a complicated respiratory problem characterized by airway inflammation, airway hyperresponsiveness (AHR), breathlessness, mucus hyper-secretion, and goblet cell hyperplasia. Asthma is controlled by genetic and environmental factors. Allergy is the main trigger of asthma and is mediated by Th2 cytokines along with IgE production. Vitamin D (Vit D) is the main supplementary factor for the immune system. In the present study, we investigated the effect of Vit D on the exacerbation of allergic asthma.

A murine model of allergic asthma was induced by ovalbumin (OVA) in four of five groups of studied female BALB/c mice (each group, n=20). One group was considered as control. Of OVA-induced mice, two groups received Vit D via oral (10,000 IU/kg diet) or intranasal (inhalation) forms (30 min on days 25, 27, and 29), and the third group received budesonide. At least, AHR, the levels of IL-4, IL-5, IL-13, and INF-g in bronchoalveolar lavage fluid (BALF), serum IgE and histamine, IL-25 and IL-33 gene expression, as well as histopathology study of the lung were done.

The Penh values, type2 Cytokines in BALF (in both protein and molecular levels), total IgE and histamine, perivascular and peribronchial inflammation, goblet cell hyperplasia, and mucus hypersecretion decreased significantly in both oral and intranasal Vit D-treated asthmatic mice groups, especially on day 38 of orally treated mice.

Here, we found Vit D as a promising agent in control of allergic asthma with a remarkable ability to decrease the severity of inflammation. Therefore, Vit D sufficiency is highly recommended in asthmatic patients.